The demonstrated clinical benefit for cancer patients in response to anti-TGF-β and anti-inflammatory drugs suggests the prospect of further investigation of the “inflammation—tumor growth” relationship, including the induction of EMT in tumor cells by an inflammatory background. The gene discussed is TGFB1; the disease is cancer.